The Inflamed Vessels: Systemic Vasculitides: Current Status and Perspectives
Systemic vasculitis is not a single disease; it is a terrifying, heterogeneous group of autoimmune disorders characterized by the relentless destruction of blood vessels, leading to devastating ischemia in the brain, kidneys, and lungs. Because the symptoms mimic countless other diseases, diagnosis is notoriously difficult and often delayed until irreversible organ damage occurs. Systemic Vasculitides: Current Status and Perspectives is the definitive, fiercely specialized text dedicated to unmasking these chameleonic diseases. This volume provides the exact blueprints required by rheumatologists and immunologists to rapidly diagnose and aggressively suppress the vascular inflammation.
Mastering ANCA and Small Vessel Disease
The core philosophy of this text is immunopathological precision. The authors aggressively detail the pathophysiology of the small vessel vasculitides, dictating exactly how Anti-Neutrophil Cytoplasmic Antibodies (ANCA) activate neutrophils to attack the vascular endothelium. It provides the crucial framework for differentiating Granulomatosis with Polyangiitis (Wegener’s) from Microscopic Polyangiitis, heavily emphasizing the role of the renal biopsy in confirming rapidly progressive glomerulonephritis.
Navigating Large Vessel Disease and Targeted Therapies
The book provides a masterclass in the broader spectrum of vascular inflammation. It dictates the exact clinical pathways for diagnosing Giant Cell Arteritis (the leading cause of preventable blindness in the elderly) and Takayasu Arteritis. It provides exhaustive reviews of modern biological therapies, detailing the revolutionary use of Rituximab (B-cell depletion) for ANCA-associated vasculitis and Tocilizumab (IL-6 receptor blockade) for large vessel disease.
Frequently Asked Questions (FAQs)
Does this book cover pediatric vasculitis?
Yes, it features critical sections on Kawasaki disease and IgA Vasculitis (Henoch-Schönlein purpura), detailing their unique clinical presentations and long-term cardiovascular risks.
Who is the primary audience?
It is the absolute, mandatory clinical guide for Rheumatologists, Immunologists, Nephrologists, and Internal Medicine Specialists.
